
To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH).A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n=40) received proxodolol, group 2 (n=20) was given carvedilol. The trial lasted for 89 days.The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
Oxadiazoles, Dose-Response Relationship, Drug, Adrenergic beta-Antagonists, Administration, Oral, Blood Pressure, Severity of Illness Index, Russia, Treatment Outcome, Delayed-Action Preparations, Hypertension, Humans, Adrenergic alpha-Antagonists, Follow-Up Studies
Oxadiazoles, Dose-Response Relationship, Drug, Adrenergic beta-Antagonists, Administration, Oral, Blood Pressure, Severity of Illness Index, Russia, Treatment Outcome, Delayed-Action Preparations, Hypertension, Humans, Adrenergic alpha-Antagonists, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
